Drug intelligence / Profile preview

3H3

Development stage
Preclinical
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal
01

Overview

3H3 is a rat-derived monoclonal antibody (IgG2a) that acts as an agonist for the 4-1BB (CD137) receptor. 4-1BB is a costimulatory molecule expressed on activated T cells and natural killer (NK) cells. By binding to 4-1BB, 3H3 provides potent costimulatory signals that enhance T-cell proliferation, survival, and effector functions, thereby promoting anti-tumor immune responses. In preclinical research, 3H3 is frequently used as a surrogate for human 4-1BB agonists to study the therapeutic potential of this pathway in murine models. Studies in multiple myeloma models have demonstrated that 3H3 can significantly reduce tumor burden and M-protein levels, particularly when combined with other immunomodulatory agents like tasquinimod, which helps overcome the immunosuppressive tumor microenvironment.

Other names
anti-4-1BB clone 3H3anti4-1BB clone 3H3anti 4-1BB clone 3H3anti-CD137 clone 3H3anti-CD-137 clone 3H3anti-CD 137 clone 3H3rat anti-mouse 4-1BB mAb
02

Targets

TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on 3H3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3H3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call